Wegovy, a weight-loss injection, will soon be available on the NHS in Scotland for patients at risk of heart disease. This decision by the Scottish Medicines Consortium (SMC) marks a significant shift in treatment options for those with a Body Mass Index (BMI) of 27 or higher who also face cardiovascular issues.
The drug works by mimicking a hormone that suppresses appetite, helping users feel fuller and potentially leading to weight loss. However, its benefits extend beyond weight management; clinical trials indicate that Wegovy may directly reduce the risk of heart attacks and strokes, which are major health concerns in Scotland.
With around 145,000 patients eligible, this initiative could transform the landscape of obesity treatment in Scotland. The SMC’s approval comes after criticism regarding the lack of access to effective weight-loss medications, which some experts have labelled a national disgrace.
As the rollout begins, patients will be able to self-administer Wegovy at home, making it a convenient option. This could lead to significant changes in healthcare outcomes, particularly in reducing the high rates of cardiovascular disease that account for over a quarter of deaths in Scotland.
Source: BBC News
